جستجوی مقالات مرتبط با کلیدواژه « ferrous sulfate » در نشریات گروه « پزشکی »

Iron deficiency anemia (IDA) is one of the most common anemias, especially in children 4–23 months. Therefore, prophylaxis is necessary to improve iron status as well as reduce IDA in Toddlers. The aim of this study was to compare the efficacy of daily supplementation with ferrous gluconate (FG) and ferrous sulfate (FS) on iron status in toddlers.

A total of 120 healthy toddlers were divided randomly into 2 groups at the Amir‑Kabir Hospital, Arak, Iran and received FS and FG from March 2020 to December 2020. Iron status was evaluated at baseline and after 6 months of supplementation. The statistical significance of the differences in iron status between FS and FG groups was calculated using Student’s t‑test and the Pearson’ s Chi‑square test for qualitative variables. SPSS software (version 16, Chicago, IL, USA) was used for statistical analysis.

Comparison of iron status of FS and FG groups toddlers at baseline and after 6 months of supplementation showed that there was a significant difference in hemoglobin (Hb) (10.46 vs. 12.45, P = 0.001) and ferritin level (28.08 vs. 59.63, P = 0.001).

Although prophylaxis with FG led to a higher Hb and ferritin levels, our study recommended that both FG and FS supplements were effective for prophylactic use in the prevention of IDA. However, FG was more effective than FS because FG group that received FG supplementation indicated a higher Hb and ferritin levels in comparison to the FS group that received FS supplementation.

In this study, the ferrous sulfate was used to remove Cr(VI) and Ni(II) ions from a real Ni-Cr plating industry wastewater. This is an applied study. The type of sampling was composite by three 5 L containers. Wastewater chemical and physical characteristics were measured in accordance with the standard methods book 14. The concentration of un-removed metal ions was estimated by ICP-OES. The Jar test type experiment was used to carry the chemical coagulation experiment. The results indicated that the rate of removal would depend on the pH estimation of 1.5-11, the diverse contact time in the range of 30-120 min and the coagulant measurement in the range of 0.5-2 g/l. The optimum Cr(VI) ions removal was gotten at a pH of 7 up to 83.88% in 0.5 g/l of coagulant dose in 40 min. While the optimum Ni(II) ions removal was found to occur at a pH of 5 up to 56.33 % in 0.5 g/l of coagulant measurements in 40 min. The scanning electron microscopy results reveal the difference between the coagulant surface when coagulation. Also, the energy-dispersive x-ray spectroscopy (EDX) analysis shows the presence of Cr(VI) and Ni(II) ions on the surface of the ferrous sulfate after coagulation. Ultimately, the outcomes indicated that ferrous sulfate could be an operative chemical coagulant to remove Cr(VI) and Ni(II) ions from the plating industry wastewater, especially for Cr(VI) particles. The outcome of this study can be a useful guide to the real plating industry wastewater treatment operators.

Anemia is prevalent in 32% to 60% of patients with cancer due to an underlying disease, nutritional deficiencies and complications of medication used in chemotherapy. National Comprehensive Cancer Network (NCCN) recommends the use of oral or intravenous iron supplementation in patients with iron deficiency anemia.

The current study aimed to determine the effectiveness of ferric carboxymaltose to improve the chronic iron deficiency anemia in patients with stage III/IV colon cancer compared with that of oral iron therapy.

The study was a controlled randomized clinical trial performed on patients with stage III/IV colon cancer referred to the Rasoul-Akram hospital in Tehran, Iran, in 2015. Hemoglobin levels less than 13 g/dL in males and less than 12 g/dL in females, ferritin levels less than 30 µg/L, serum iron levels less than 50 µg/dL and total iron binding capacity (TIBC) levels less than 360 µg/dL are considered as chronic iron deficiency anemia. Patients with stage III/IV colon cancer and chronic iron deficiency anemia were enrolled. Non-compliance with the treatment regimen, intolerable side effects and lack of follow-up were the measures of exclusion from the study. Patients were selected based on the block balanced randomization and divided into two groups. The first group received the standard treatment of oral ferrous sulfate (65 mg three times a day for two months), and the second group received injection vials of ferric carboxymaltose (1500 mg for patients weighing less than 70 kg, 2000 mg for more than 70 kg).

Ten patients (five in the first group and five in the second group) were excluded due to lack of follow-up tests. In each group, 30 patients were considered in the final analysis. Analysis showed that patients who received ferric carboxymaltose had higher levels of hemoglobin and ferritin compared to patients who received ferrous sulfate (P = 0.000). The results showed that increased levels of hemoglobin in iron sulfate had no significant differences regarding gender (male or female) and the stage of the disease; although in the carboxymaltose group, improved levels of hemoglobin were significantly better in females than males (P = 0.034). Also, the level of ferritin in iron sulfate group showed a better increase in females compared to males (P = 0.007).

Findings of the study showed that using the parenteral iron formulation of carboxymaltose had an excellent efficacy in improving iron deficiency anemia in patients with high rates of colon cancer compared with that of oral ferrous sulfate. This effect is mostly related to the proper formulation of ferric carboxymaltose, which results in a stable and continuous increase in the levels of ferritin and hemoglobin in patients.